On or around 10/03/2016 (Date of last review)
Filing Date: May 22, 2015
According to the law firm press release, the lawsuit alleges Defendants made false and/or misleading statements regarding IsoRay’s Celsium-131 isotope seeds and mesh for the treatment of non-small cell lung cancers. When the true details entered the market, shares of IsoRay fell $1.10 per share or over 35% to close at $2.02 per share on May 21, 2015, damaging investors.
On July 29, 2015, this case was transferred to the Eastern District of Washington.
An amended complaint was filed on October 16, 2015.
On September 23, 2016, the parties entered into a Stipulation of Settlement.
Company & Securities Information
Defendant: IsoRay, Inc.
Industry: Medical Equipment & Supplies
Headquarters: United States
Ticker Symbol: ISR
Company Market: New York SE
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.